Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 261 | 98 | 10 |
Full Text Views | 5 | 1 | 0 |
PDF Downloads | 2 | 1 | 0 |
The symposium provided dramatic evidence of the value of the use of polyamine inhibition via α-difluoromethylornithine (DFMO, eflornithine) for advances in chemotherapy of Trypanosoma brucei gambiense sleeping sickness and Pneumocystis carinii pneumonia in acquired immune deficiency syndrome (AIDS) and also for further understanding the metabolic importance of the ubiquitous polyamines in these organisms.